PatSnap/clinical-trial huggingface dataset:
Clinical trial NCT02415569: Tailored Bowel Preparation According to Bristol Stool Form Scale
Official title: Tailored Bowel Preparation According to Bristol Stool Form Scale: a Prospective, Randomized, Controlled, Investigator-blinded, Multicenter Study
Conditions: Bowel Cleansing Quality
Summary: The Bristol stool form scale ( BSFS) based tailored bowel cleansing regimen might be helpful to improve bowel cleansing quality before colonoscopy.
Interventions:
description: Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
name: Standard Bowel Prep (2L PEG-ELP)
type: Drug
description: Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure.
name: 2L PEG-ELP and 10mg bisacodyl
type: Drug
description: Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
name: Standard Bowel Prep (2L PEG-ELP)
type: Drug
Study arms:
design_group_description: Subjects whose bristol stool forms are type 1 or 2, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
design_group_title: group1
design_group_type: Experimental
design_group_description: Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure. ( 2L PEG-ELP and 10mg bisacodyl )
design_group_title: group2
design_group_type: Experimental
design_group_description: Subjects whose bristol stool forms are type 3 to 7, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
design_group_title: group3
design_group_type: Active Comparator
Sponsor: Shandong University
Collaborators: Qianfoshan Hospital of Shandong Province
Drug name mappings:
name: 比沙可啶
lang: CN
name: Bisacodyl
lang: EN
name: ビサコジル
lang: JP
Clinical trial NCT00941785: Dihydroartemisinin (DHA)-Piperaquine for IPT to Prevent Malaria in Children in Burkina Faso
Official title: Randomized Trial of the Efficacy, Safety, Tolerability and Pharmacokinetics of Dihydroartemisinin-piperaquine for Seasonal IPT to Prevent Malaria in Children Under 5 Years
Conditions: Malaria
Summary: The aim of the study is to determine whether piperaquine plus dihydroartemisinin (DHA-PQ) is as effective, and better tolerated, than sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ), when used for seasonal Intermittent Preventive Treatment (IPT) to prevent malaria in children aged 3 to 59 months in Bobo-Dioulasso, Burkina Faso and to determine the pharmacokinetics of piperaquine in children.
Interventions:
description: Three monthly administrations of Duocotexcin (DHA-PQ):<br/>dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days
name: DHA-PQ
other_name: Seasonal IPTc with Duocotexcin (Holley)
type: Drug
description: Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine:<br/>One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg
name: SP-AQ
other_name: Seasonal IPTc with Fansidar plus amodiaquine (Flavoquine)
type: Drug
Study arms:
design_group_description: Three monthly administrations of dihydroartemisinin (DHA) plus piperaquine (PQ) in August, September and October.
design_group_title: DHA-PQ
design_group_type: Experimental
design_group_description: Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine
design_group_title: SP-AQ
design_group_type: Active Comparator
Sponsor: London School of Hygiene & Tropical Medicine
Collaborators: Beijing Holley-Cotec Pharmaceuticals Co. Ltd.
Drug name mappings:
name: 双氢青蒿素哌喹
lang: CN
name: Piperaquine tetraphosphate/Artenimol
lang: EN
Clinical trial NCT01790685: Ozurdex for Retinal Vein Occlusion Study (ORVO Study)
Official title: Ozurdex for Retinal Vein Occlusion Study (ORVO Study)
Conditions: Retinal Vein Occlusion
Summary: To measure the pro-permeability factors in the aqueous humor of patients with persistent/recurrent macular edema after an injection of Ozurdex.
Interventions:
name: dexamethasone implant
other_name: Ozurdex
type: Drug
Study arms:
design_group_description: Central Retinal Vein Occlusion
design_group_title: CRVO
design_group_type: Other
design_group_description: Branch Retinal Vein Occlusion
design_group_title: BRVO
design_group_type: Other
Sponsor: The Johns Hopkins University
Collaborators: Allergan UC
Drug name mappings:
name: 地塞米松
lang: CN
name: Dexamethasone
lang: EN
name: デキサメタゾン
lang: JP
Clinical trial NCT00204698: Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment
Official title: Identification of Molecular Markers of Inflammatory Mediators in Posterior Laryngitis Due to Laryngopharyngeal Reflux and Evolution With PPI Treatment
Conditions: Laryngopharyngeal Reflux
Summary: This study proposes to investigate prospectively, the presence of molecular markers for inflammation in laryngopharyngeal reflux (LPR) patients and to study the effect of a proton pump inhibitor (Aciphex) on these molecular markers.
The investigators will be evaluating a group of patients before and after treatment. This group will be patients that have untreated laryngopharyngeal reflux diagnosed by laryngoscopic assessment and a 24-hour probe.
Interventions:
description: 20 mg of aciphex taken twice daily
name: Aciphex
type: Drug
Study arms:
design_group_description: All subjects will be given active drug.
design_group_title: 1
design_group_type: Active Comparator
Sponsor: University of Utah
Collaborators: Pricara
Drug name mappings:
name: 雷贝拉唑钠
lang: CN
name: Rabeprazole Sodium
lang: EN
name: ラベプラゾールナトリウム
lang: JP
Clinical trial NCT00114400: BVAIT: B-Vitamin Atherosclerosis Intervention Trial
Official title: B-Vitamin Atherosclerosis Intervention Trial (BVAIT)
Conditions: Atherosclerosis
Summary: The purpose of this study is to examine whether vitamin B supplementation will reduce the progression of early atherosclerosis in individuals over 40 years old and without clinical evidence of cardiovascular disease (CVD).
Interventions:
name: folic acid
type: Drug
name: vitamin B12
type: Drug
name: vitamin B6
type: Drug
Study arms:
Sponsor: National Institute on Aging
Collaborators: Leiner Health Products, Inc.
Drug name mappings:
name: 维生素B12
lang: CN
name: Cyanocobalamin
lang: EN
name: シアノコバラミン
lang: JP
name: 叶酸
lang: CN
name: Folic Acid
lang: EN
name: 维生素B6
lang: CN
name: Pyridoxine Hydrochloride
lang: EN
name: ピリドキシン塩酸塩
lang: JP
Clinical trial NCT04315298: Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Official title: An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19
Conditions: COVID-19
Summary: Phase 2:
The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata.
Phase 3 Cohort 1:
The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with critical COVID-19 receiving mechanical ventilation at baseline.
Phase 3 Cohort 2:
The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 receiving mechanical ventilation at baseline.
Interventions:
description: Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.
name: Sarilumab
other_name: Kevzara®
REGN88
SAR153191
type: Drug
description: Single or multiple intravenous (IV) doses of placebo to match sarilumab administration
name: Placebo
type: Drug
Study arms:
design_group_description: Phase 2
design_group_title: Sarilumab 200mg IV (P2)
design_group_type: Experimental
design_group_description: Phase 3: Cohort 1
design_group_title: Sarilumab 200mg IV (P3:C1)
design_group_type: Experimental
design_group_description: Phase 2
design_group_title: Sarilumab 400mg IV (P2)
design_group_type: Experimental
design_group_description: Phase 3: Cohort 1
design_group_title: Sarilumab 400mg IV (P3:C1)
design_group_type: Experimental
design_group_description: Phase 3: Cohort 2
design_group_title: Sarilumab 800mg IV (P3:C2)
design_group_type: Experimental
design_group_description: Phase 3: Cohort 3
design_group_title: Sarilumab 800mg IV (P3: C3)
design_group_type: Experimental
Sponsor: Regeneron Pharmaceuticals, Inc.
Collaborators: Sanofi
Drug name mappings:
name: 沙利鲁单抗
lang: CN
name: Sarilumab
lang: EN
name: サリルマブ（遺伝子組換え）
lang: JP
Clinical trial NCT04288232: Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
Official title: A Multicenter, Open-label, Prospective, Interventional Study to Assess the Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
Conditions: Center-involved Diabetic Macular Edema
Summary: Phase IIIb, multicenter, open-label, prospective, interventional study to assess the potential benefit of Aflibercept treatment administered IVT at a dosage of 2 mg with five monthly loading doses and then treat and extend over 48 weeks, with the primary endpoint as BCVA assessed at Week 52.
Interventions:
description: Intravitreal aflibercept Injection 2.0mg/0.05 ml
name: Aflibercept Injection [Eylea]
type: Drug
Study arms:
design_group_description: Intravitreal injection of aflibercept 2.0mg/0.05 ml Aflibercept was administered with 5 monthly loadings followed by treat-and-extend with a 4-week interval increment/decrement with maxima cap at 12 weeks to visual/anatomic stability.
design_group_title: Intravitreal aflibercept
design_group_type: Experimental
Sponsor: Taipei Veterans General Hospital
Collaborators: National Taiwan University Hospital
Chang Gung Memorial Hospital
Drug name mappings:
name: 阿柏西普
lang: CN
name: Aflibercept
lang: EN
name: アフリベルセプト（遺伝子組換え）
lang: JP
Clinical trial NCT01391858: Postoperative Pain and Morphine Consumption After Mastectomy - Lyrica
Official title: Effects of Oral Pregabalin Versus Placebo on Postoperative Pain and Morphine Consumption After Mastectomy
Conditions: Post-operative Pain
Summary: This study will compare the effects of oral pregabalin with placebo on postoperative pain and morphine usage after mastectomy.
Pregabalin is an anticonvulsant agent approved by the United States Food and Drug Administration (FDA) for the treatment of neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy.
Women 18-70 years of age, undergoing unilateral modified mastectomy or lumpectomy with axillary node dissection will be recruited to participate in the study. Patients unable to cooperative, those that have known allergy to pregabalin or morphine and a history of drug or alcohol abuse, chronic pain, history of daily intake of analgesics or steroids, or impaired kidney function will all be excluded from the study. A pregnancy test will also be performed to exclude pregnant women from the study.
Oral pregabalin 300 mg (or placebo) will be administered to patients 1-2 hours before surgery followed by 150 mg 12 hours later. Thereafter, 150 mg of oral pregabalin (or placebo) will be administered twice daily until day 14. Whether a patient receives pregabalin or placebo will be decided based on a process similar to tossing a coin.
Patients will receive a standard general anesthetic for their operation and will receive intravenous patient-controlled analgesia (PCA) morphine for pain in the immediate postoperative period. Oral opioids will be administered after discontinuation of the PCA.
Subjects will be visited after the operation while in the hospital and intermittently for three months at the outpatient clinic after discharge from the hospital. Subjects will be asked to return remaining study drug/empty container when they are at the hospital for their 2 week follow up visit.
Potential adverse effects of pregabalin include dizziness, somnolence, peripheral edema, weight gain, headache, dry mouth, blurry vision, and ataxia. The incidence of these side effects occurring ranges variously between 1 and 25%. Investigators will closely monitor all patients for the occurrence of these side effects.
Interventions:
description: 150mg of pregabalin/placebo
name: lyrica
other_name: pregabalin
type: Drug
Study arms:
design_group_description: pregabalin (lyrica)
design_group_title: pregabalin
design_group_type: Active Comparator
design_group_description: placebo
design_group_title: placebo
design_group_type: Placebo Comparator
Sponsor: The University of Texas Southwestern Medical Center
Collaborators: Pfizer Inc.
Drug name mappings:
name: 普瑞巴林
lang: CN
name: Pregabalin
lang: EN
name: プレガバリン
lang: JP
Clinical trial NCT00435370: Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia
Official title: Tropisetron With Risperidone for Schizophrenia
Conditions: Smoking Cessation
Schizophrenia
Summary: This study will determine the effectiveness of tropisetron plus risperidone in improving cognitive symptoms in Chinese people with schizophrenia.
Interventions:
description: 10 mg/day
name: Tropisetron
other_name: Navoban
type: Drug
description: placebo
name: Placebo
type: Drug
description: 6mg/day
name: Risperidone
other_name: Risperdal, Ridal, Rispolept
type: Drug
Study arms:
design_group_description: Tropisetron (10mg/day) + risperidone(6mg/day)
design_group_title: Tropisetron
design_group_type: Experimental
design_group_description: Placebo + risperidone (6mg/day)
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: Baylor College of Medicine
Collaborators: National Institute of Mental Health
Drug name mappings:
name: 利培酮
lang: CN
name: Risperidone
lang: EN
name: リスペリドン
lang: JP
name: 盐酸托烷司琼
lang: CN
name: Tropisetron hydrochloride
lang: EN
Clinical trial NCT01802749: Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
Official title: Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line
Conditions: Recurrent Ovarian Cancer
Summary: Bevacizumab has been found to prolong progression free survival in first line, and more recently, in second line treatment for platinum sensitive ovarian cancer patients who had not received prior treatment with bevacizumab.
Recently reported data suggest that patients with colon cancer who receive bevacizumab in more than one line of therapy (beyond progression) have better results. In ovarian cancer, the role of bevacizumab administered in both first and second-line therapies needs to be defined.
This study aims to evaluate whether administering bevacizumab in combination with chemotherapy in second-line therapy to patients with recurrent ovarian cancer who have received first-line bevacizumab will be more effective than chemotherapy alone.
Interventions:
name: Bevacizumab
other_name: Avastin
type: Drug
name: Paclitaxel
type: Drug
name: Carboplatin
type: Drug
name: pegylated liposomal doxorubicin
other_name: Caelyx
type: Drug
name: Gemcitabine
type: Drug
Study arms:
design_group_description: Combination chemotherapy with ONE of the following regimens:<br/>* PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC (area under curve) 5 on day 1 every 4 weeks;<br/>* GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days;<br/>* PAC-C: Paclitaxel 175 mg/m2 on day 1, every 21 + Carboplatin AUC of 5 on day 1 every 21 days.
design_group_title: chemotherapy
design_group_type: Active Comparator
design_group_description: Combination chemotherapy AND bevacizumab with ONE of the following regimens:<br/>* PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC 5 on day 1 every 4 weeks and Bevacizumab 10 mg/kg i.v. on Day 1 every 2 weeks;<br/>* GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days AND Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks;L<br/>* PAC-C: Paclitaxel 175 mg/m2 on day 1, every 21 + Carboplatin AUC of 5 on day 1 every 21 days AND Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks.<br/>Patients whose disease has not progressed after the initial six cycles of combination treatment will continue bevacizumab, at 15 mg/kg every 3 weeks until disease progression,unacceptable toxicity or patient withdrawn.
design_group_title: Chemotherapy and bevacizumab
design_group_type: Experimental
Sponsor: National Cancer Institute
Collaborators: Istituto di Ricerche Farmacologiche Mario Negri
Drug name mappings:
name: 盐酸多柔比星脂质体
lang: CN
name: Doxorubicin Hydrochloride liposomal
lang: EN
name: 卡铂
lang: CN
name: Carboplatin
lang: EN
name: カルボプラチン
lang: JP
name: 盐酸吉西他滨
lang: CN
name: Gemcitabine Hydrochloride
lang: EN
name: ゲムシタビン塩酸塩
lang: JP
name: 紫杉醇
lang: CN
name: Paclitaxel
lang: EN
name: パクリタキセル
lang: JP
name: 贝伐珠单抗
lang: CN
name: Bevacizumab
lang: EN
name: ベバシズマブ（遺伝子組換え）
lang: JP
Clinical trial NCT02839330: A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
Official title: A Phase 3 Randomized, Observer-Blind, Multi-center, Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
Conditions: Avian Influenza
Summary: This Phase 3 study evaluates the safety, immunogenicity and lot-to lot consistency of 3 lots of aH5N1c vaccine for pandemic avian influenza, in approximately 2394 healthy adults ≥18 years of age receiving the vaccine and 797 healthy adults receiving placebo. Subjects were randomized in a 3:1 ratio to receive either aH5N1c vaccine or saline placebo. Enrollment was stratified by age: 18 to <65 years of age and ≥65 years of age, to allow adequate safety assessment of the entire age spectrum.
Interventions:
description: Intramuscular (IM) administration, containing 7.5 mcg H5N1 hemagglutinin antigen (HA) + 0.25 mL MF59 (approximately 0.5 mL total volume).
name: aH5N1c
type: Biological
description: Placebo: Saline injection
name: Placebo
type: Biological
Study arms:
design_group_description: aH5N1c lot #1; receive 2 doses (on Day 1 and Day 22)
design_group_title: Group A
design_group_type: Experimental
design_group_description: aH5N1c lot #2; receive 2 doses (on Day 1 and Day 22)
design_group_title: Group B
design_group_type: Experimental
design_group_description: aH5N1c lot #3; receive 2 doses (on Day 1 and Day 22)
design_group_title: Group C
design_group_type: Experimental
design_group_description: Placebo; receive 2 doses (on Day 1 and Day 22)
design_group_title: Group D
design_group_type: Placebo Comparator
Sponsor: Seqirus GmbH
Collaborators: Biomedical Advanced Research & Development Authority (Barda)
Drug name mappings:
name: Influenza A (H5N1) monovalent vaccine, adjuvanted(CSL Ltd.)
lang: EN
Clinical trial NCT04661280: Donepezil Versus Non-drug Treatment in Alzheimer's Disease.
Official title: Donepezil Use Versus Non-drug Approach in Treatment of Newly Diagnosed Alzheimer's Disease : a Multicentric, Randomized, Open Study : the CHOLINE-2 Study
Conditions: Alzheimer Disease, Early Onset
Summary: Donepezil, as well as the other symptomatic drugs of Alzheimer's disease, is not any more reimbursed by the French healthcare system, due to a controversy about its efficiency. French health authorities currently preconize a non-rug approach based on cognitive remediation or stimulation.
The aim of this study is to compare the efficiency of the 2 approaches (non-drug versus donepezil) on the symptoms of Alzheimer's disease after 6 months of treatment.
Interventions:
description: Donepezil 5 mg per day during one month, then 10 mg per day during 5 months.
name: Donepezil
other_name: Aricept
type: Drug
Study arms:
design_group_description: Non-drug treatment, cognitive remediation, cognitive stimulation
design_group_title: Cognitive remediation
design_group_type: No Intervention
design_group_description: Non-drug treatment, cognitive remediation, cognitive stimulation + Donepezil
design_group_title: Cognitive remediation + Donepezil
design_group_type: Experimental
Sponsor: Assistance Publique des Hôpitaux de Paris SA
Collaborators: Association France Alzheimer
Drug name mappings:
name: 盐酸多奈哌齐
lang: CN
name: Donepezil Hydrochloride
lang: EN
name: ドネペジル塩酸塩
lang: JP
Clinical trial NCT04453826: Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
Official title: A Multicenter Randomized Clinical Phase 3 Trial of Induction Chemotherapy Plus Concurrent Chemo-radiotherapy With or Without Camrelizumab for High Risk Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Cancer
Chemotherapy
Radiotherapy
PD-1 Therapy
Summary: Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that concurrent and adjuvant PD-1 treatment added to chemo-radiotherapy could further decrease the rate of disease progression and improve the survival outcome of high risk patients with nasopharyngeal carcinoma compared with those treated with chemo-radiotherapy alone.
Interventions:
description: 1. Camrelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of camrelizumab are concurrently used during radiotherapy and camrelizumab are maintained for 1 year after the end of radiotherapy.<br/>2. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.<br/>3. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.<br/>4. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy
name: Camrelizumab plus chemo-radiotherapy
type: Drug
description: 1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.<br/>2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.<br/>3. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy
name: Chemo-radiotherapy alone
type: Drug
Study arms:
design_group_description: 3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent chemo-radiotherapy with concurrent and adjuvant camrelizumab therapy.
design_group_title: Camrelizumab plus chemo-radiotherapy arm
design_group_type: Experimental
design_group_description: 3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent chemo-radiotherapy.
design_group_title: Chemo-radiotherapy arm
design_group_type: Active Comparator
Sponsor: Sun Yat-Sen University
Collaborators: Affiliated Tumor Hospital of Guangzhou Medical University
Zhongshan People's Hospital
Yue Bei People's Hospital
the First Affiliated Hospital of Sun Yat-Sen University
Drug name mappings:
name: 卡瑞利珠单抗
lang: CN
name: Camrelizumab
lang: EN